Azurity Pharma Inc v. Strides Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Azurity Pharmaceuticals, Inc. (Delaware)
  • Defendant: Strides Pharma Inc. (New Jersey) and Strides Pharma Global PTE Ltd. (Singapore)
  • Plaintiff's Counsel: Robinson Miller LLC
• Case Identification: 1:25-cv-16717, D.N.J., 07/13/2026
• Venue Allegations: Venue is alleged based on Defendant Strides Pharma Inc. having a regular and established place of business in New Jersey, both defendants regularly conducting business in the state, and their previous submission to the court's jurisdiction in other matters.
• Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's SUFLAVE® drug product constitutes an act of infringement of three patents related to colon cleansing compositions and methods.
• Technical Context: The technology concerns chemical formulations for clearing the colon prior to medical procedures like colonoscopies, focusing on improving patient tolerance, safety, and efficacy compared to earlier preparations.
• Key Procedural History: This is an ANDA litigation initiated under the Hatch-Waxman Act. The original plaintiff, Braintree Laboratories, Inc., filed the suit after receiving a notice letter from Strides. Azurity Pharmaceuticals, Inc. later acquired the rights to the SUFLAVE® product and was substituted as the plaintiff during the litigation.

Case Timeline

Date	Event
2023-06-15	Earliest Priority Date for all Asserted Patents ('529, '914, '298 Patents)
2023-06-15	Plaintiff's SUFLAVE® product receives FDA approval (NDA No. 215344)
2025-05-06	U.S. Patent No. 12,290,529 ('529 Patent) Issued
2025-09-03	Defendants send notice letter regarding ANDA No. 220202
2025-10-07	U.S. Patent No. 12,433,914 ('914 Patent) Issued
2025-11-17	Azurity acquires U.S. rights to SUFLAVE® from Braintree Laboratories, Inc.
2025-11-19	Azurity substituted as Plaintiff in the litigation
2026-03-18	Defendants send supplemental notice letter
2026-04-07	U.S. Patent No. 12,594,298 ('298 Patent) Issued
2026-07-13	Second Amended Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,290,529 - "Methods of Administering Safe Colon Cleansing Compositions," issued May 6, 2025

The Invention Explained

• Problem Addressed: The patent's background describes challenges with prior art colon cleansing preparations. Large-volume solutions based on polyethylene glycol (PEG) suffer from poor patient compliance due to the large amount of salty-tasting liquid required. Smaller-volume alternatives based on phosphate salts carried a risk of renal failure, while other low-volume options required adjunct stimulant laxatives that could cause cramping and bloating and had their own safety concerns. '529 Patent, col. 1:10-64
• The Patented Solution: The invention is a colon cleansing composition and method that combines PEG with a specific mixture of sulfate salts (sodium sulfate, magnesium sulfate) and other electrolytes (potassium chloride, sodium chloride). This formulation is designed to be effective in a lower, more tolerable volume without requiring adjunct laxatives. A key aspect is the inclusion of a specific flavoring system (acidic components, non-fermentable sweeteners) that masks the poor taste of the salts and PEG, improving patient compliance while maintaining a satisfactory safety profile, particularly regarding electrolyte balance. '529 Patent, abstract '529 Patent, col. 2:10-28
• Technical Importance: This approach sought to create a "best of both worlds" solution by combining the safety of PEG-based solutions with the tolerability of lower-volume preparations, thereby improving the quality of colonoscopies through better patient compliance and cleansing. '529 Patent, col. 7:1-8

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶38
• Essential Elements of Independent Claim 1 (Product Claim):
  • A first container comprising a first portion of a first dose including specific amounts of polyethylene glycol (PEG) 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride.
  • A second container comprising a second portion of the first dose, including malic acid and citric acid.
  • A third container comprising a first portion of a second dose with the same ingredients as the first container.
  • A fourth container comprising a second portion of the second dose with malic acid and citric acid.
  • The product further comprises lemon-lime flavor, sucralose, and neotame.
  • The product is formulated so that the combined doses "cleanse a colon of a subject without causing a sodium balance of -50.00 mEq/L or greater in the subject." '529 Patent, cl. 1

U.S. Patent No. 12,433,914 - "Methods of Administering Safe Colon Cleansing Compositions," issued October 7, 2025

The Invention Explained

• Problem Addressed: The patent addresses the same technical problems as the '529 Patent: the need for a colon cleansing regimen that is effective, safe, palatable, and requires a lower volume of liquid than traditional preparations to ensure patient compliance. '914 Patent, col. 1:10-55
• The Patented Solution: The solution is a method of administering a PEG and sulfate-based formulation. The method involves a split-dosing regimen where a patient consumes a first dose and then, after a period of time, a second dose. This method, using the specified composition, is described as cleansing the colon sufficiently for medical procedures without causing significant electrolyte shifts. '914 Patent, abstract '914 Patent, col. 2:10-28
• Technical Importance: This patent focuses on the method of use, standardizing an administration protocol for the novel formulation to ensure both efficacy and safety, particularly the maintenance of a safe sodium balance in the patient. '914 Patent, col. 18:20-42

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶46
• Essential Elements of Independent Claim 1 (Method Claim):
  • Administering to a patient a first dose of a colon cleansing product comprising specific amounts of PEG, sodium sulfate, potassium chloride, magnesium sulfate, sodium chloride, malic acid, and citric acid, mixed in water.
  • Administering to the patient a second dose of the same product composition.
  • Wherein the consumption of both doses "cleanses the colon of the patient sufficiently for diagnostic and surgical procedures to be performed."
  • Wherein the combined doses do "not cause a sodium balance of -50.00 mEq/L or greater in the patient." '914 Patent, cl. 1

U.S. Patent No. 12,594,298 - "Methods of Administering Safe Colon Cleansing Compositions," issued April 7, 2026

Technology Synopsis

This patent, part of the same family, also addresses the need for a palatable, safe, and effective low-volume colon cleansing preparation. The invention described is a product comprising PEG and a mixture of sulfate salts, formulated with specific flavoring agents to be effective without adjunct laxatives and to be well-tolerated by patients, thereby improving compliance. '298 Patent, abstract '298 Patent, col. 1:10-64

Asserted Claims

At least independent claim 1 Compl. ¶54

Accused Features

The complaint alleges that Defendants' proposed generic version of SUFLAVE®, which contains PEG 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride, will infringe the patent. Compl. ¶54

III. The Accused Instrumentality

Product Identification

The accused instrumentality is the proposed generic drug product described in Defendants' ANDA No. 220202, intended to be a generic version of Azurity's SUFLAVE® Compl. ¶¶1; Compl. ¶5

Functionality and Market Context

The complaint alleges that the accused product has the "same active ingredients, the same route of administration, the same dosage form, and the same strengths as the corresponding components of SUFLAVE®" Compl. ¶32 The product is a colon cleansing solution containing polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride Compl. ¶37 The complaint further alleges that Defendants have represented to the FDA that their proposed generic product is bioequivalent to SUFLAVE® Compl. ¶32 If approved, the product would be marketed as a lower-cost generic alternative for colon cleansing in preparation for colonoscopy in adults Compl. ¶¶5; Compl. ¶15

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'529 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A colon cleansing product comprising: (a) a first container comprising a first portion of a first dose... (b) a second container comprising a second portion of the first dose... (c) a third container... (d) a fourth container...	The complaint alleges the proposed generic product is a bioequivalent version of SUFLAVE® and contains the same active ingredients in the same strengths, implying a similar kitted structure.	¶32; ¶38	col. 18:5-39
wherein the colon cleansing product further comprises lemon-lime flavor, sucralose, and neotame;	The complaint alleges the composition and proposed use of the generic product are the same as SUFLAVE®, which contains these or equivalent flavoring agents.	¶38	col. 18:40-42
and wherein the colon cleansing product is formulated so that the combination of the first dose and second dose cleanse a colon of a subject without causing a sodium balance of -50.00 mEq/L or greater in the subject.	It is alleged that because the accused product is bioequivalent to SUFLAVE®, it will perform substantially the same function to obtain the same result, including meeting this specified safety profile.	¶32; ¶40	col. 18:43-49

'914 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of cleansing a colon of a patient, the method comprising: (a) administering to the patient a first dose... (b) administering to the patient a second dose of the colon cleansing product...	The complaint alleges the proposed labeling for the generic product will instruct physicians and patients to administer the drug in a split-dosing regimen that mirrors the claimed method.	¶41; ¶49	col. 12:4-15
wherein consumption of the first dose and second dose cleanses the colon of the patient sufficiently for diagnostic and surgical procedures to be performed,	It is alleged that the instructions for use on the proposed product label will direct a use that achieves this result, and that the product is not suitable for any substantial non-infringing use.	¶41; ¶49	col. 12:13-16
and wherein the combination of the first dose and the second dose does not cause a sodium balance of -50.00 mEq/L or greater in the patient.	The complaint alleges infringement because the proposed generic product is represented as bioequivalent, suggesting it will achieve the same clinical safety outcome when used as directed.	¶32; ¶40	col. 18:38-42

• Identified Points of Contention:
  • Functional Limitation Question: A primary point of contention may be the negative limitation "without causing a sodium balance of -50.00 mEq/L or greater." The complaint's theory appears to rest on the allegation of bioequivalence Compl. ¶32; Compl. ¶40 A question for the court will be whether this allegation is sufficient to plead infringement of this functional, clinical-outcome limitation, or if more direct evidence related to the Defendants' specific formulation is required.
  • Structural Question: For the '529 Patent's product claim, a potential issue is whether the physical packaging of Defendants' proposed generic product will map directly onto the "first container," "second container," "third container," and "fourth container" structure recited in the claim.

V. Key Claim Terms for Construction

• The Term: "without causing a sodium balance of -50.00 mEq/L or greater in the subject"

  • Context and Importance: This term appears in the independent claims of both the '529 and '914 patents and defines a critical safety feature of the invention. The infringement analysis for all asserted patents may hinge on whether the accused product meets this negative functional limitation. Practitioners may focus on this term because it ties the claim scope to a specific clinical outcome, which can be a focal point for disputes over both infringement and definiteness.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party might argue the term should be interpreted in light of the patent's overall objective to create a safer alternative. The specification's description of the invention as avoiding "clinically significant electrolyte shifts" could support an interpretation where any bioequivalent formulation that achieves this general goal falls within the claim's scope. '529 Patent, col. 7:5-8
    • Evidence for a Narrower Interpretation: The specification provides specific clinical trial data for a preferred embodiment (BLI4900-5), which exhibited a mean sodium balance of -13.00 mEq/L. '529 Patent, col. 17-18, Table 2 A party could argue the term should be construed narrowly in light of this specific example, potentially requiring any accused product to be evaluated against this concrete data point.

• The Term: "container"

  • Context and Importance: This term is central to the structure of product claim 1 of the '529 Patent, which recites a kit with four distinct containers. The determination of infringement will depend on whether the packaging of the accused generic product constitutes four separate "containers" as the term is construed.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent uses the term without providing a specific definition or limiting examples (e.g., bottle, pouch, sachet). The specification states the method includes "providing a first container" and "providing a second container," suggesting any two distinct physical vessels holding the separate components would suffice. '529 Patent, col. 12:27-46 This lack of specialization may support a broad, plain-meaning construction.
    • Evidence for a Narrower Interpretation: A party seeking a narrower construction might argue that the term implies a certain level of physical separation and intended use inherent in a multi-part pharmaceutical kit. However, the intrinsic evidence does not appear to provide significant support for a definition narrower than its ordinary meaning in the context of packaging.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Defendants will induce and contribute to infringement. The basis for inducement is the allegation that Defendants' proposed product labeling will instruct physicians and patients to use the generic product in an infringing manner Compl. ¶41; Compl. ¶49; Compl. ¶57 Contributory infringement is alleged on the basis that the proposed product and its labeling are "especially made or adapted for use in infringing" the patents and are "not suitable for any substantial non-infringing use" Compl. ¶41; Compl. ¶49; Compl. ¶57
• Willful Infringement: The complaint does not use the word "willful," but it lays a foundation for such a claim. It alleges that Defendants had "actual and constructive knowledge" of the asserted patents prior to and at the time of filing their ANDA, and were aware that the filing constituted an act of infringement Compl. ¶39; Compl. ¶47; Compl. ¶55 These allegations of pre-suit knowledge may be used to support a claim for enhanced damages.

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of clinical equivalence: will the Defendants' representation of bioequivalence to the FDA be sufficient for the court to determine, as a matter of law or fact, that their generic product will meet the claimed functional limitation of not causing a sodium balance of -50.00 mEq/L or greater, or will specific evidence on the performance of the accused product be required?
• A key evidentiary question will be one of induced infringement: does the language of the Defendants' proposed product label, as submitted in their ANDA, contain explicit instructions or recommendations that would direct medical professionals and patients to carry out every step of the asserted method claims, thereby establishing the requisite intent for inducement?
• A structural question specific to the asserted product claims will be one of kit construction: does the physical packaging of the defendants' proposed generic product-as a complete, marketed item-fall within the scope of the claims requiring a specific arrangement of four separate "containers"?